Related Experiment Video

Updated: Aug 26, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Dopamine agonist 3-PPP fails to protect against MPTP-induced toxicity

Dhanasekaran Muralikrishnan1, Manuchair Ebadi, Holly M Brown-Borg

  • 1Department of Pharmacology, Physiology and Therapeutics, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota 58203, USA.

Neurochemical Research
|March 9, 2004
PubMed

Insights

The dopamine agonist 3-PPP did not protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. This study found 3-PPP ineffective in preventing dopamine depletion or neuroprotection in mouse models.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neurotoxicology

Background:

  • 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin that causes Parkinsonism by depleting dopamine.
  • Dopamine agonists are explored for potential neuroprotective effects in Parkinson's disease models.
  • 3-PPP (3-(3-hydroxyphenyl)-N-propylpiperidine) is a dopamine agonist investigated for its neuroprotective capabilities.

Purpose of the Study:

  • To investigate the neuroprotective effect of the dopamine agonist 3-PPP against MPTP-induced neurotoxicity.
  • To determine if 3-PPP modulates dopamine levels, uptake, or monoamine oxidase-B activity in the context of MPTP exposure.
  • To assess the impact of 3-PPP on dopaminergic neuronal cell proliferation and MPP+-induced cytotoxicity.

Main Methods:

  • MPTP was administered to mice to induce neurotoxicity and dopamine depletion in the nucleus caudatus putamen (NCP).
  • The effects of 3-PPP on monoamine oxidase-B activity and dopamine uptake in NCP were assessed.
  • SH-SY5Y dopaminergic neuronal cells were used to evaluate the impact of MPP+ and 3-PPP on cell proliferation and cytotoxicity.

Main Results:

  • MPTP significantly depleted dopamine in the NCP.
  • 3-PPP did not affect monoamine oxidase-B activity or dopamine uptake.
  • 3-PPP did not prevent MPTP-induced behavioral changes or dopamine depletion, nor did it protect SH-SY5Y cells from MPP+-induced cytotoxicity.

Conclusions:

  • The dopamine agonist 3-PPP demonstrated no neuroprotective effect against MPTP-induced dopaminergic neurotoxicity.
  • 3-PPP did not interfere with the mechanisms of MPTP neurotoxicity, including dopamine depletion or direct cellular toxicity.
  • These findings suggest that 3-PPP is not a viable therapeutic candidate for mitigating MPTP-induced neurodegeneration.

More Related Videos

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...